Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant

Paul Y. Kwo, Marwan Ghabril, Marco A. Lacerda, Alfred Joseph Tector, Jonathan A. Fridell, Rodrigo Vianna

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Introduction: Aggressive recurrence of hepatitis C remains problematic post-orthotopic liver transplant (OLT). There are limited data on treatment of HCV infection with telaprevir/boceprevir therapy with peginterferon/ribavirin (PR) post-OLT. Aim: To review our experience with telaprevir addition to peginterferon/ribavirin in treatment of aggressive hepatitis C in null responders to PR post-OLT. Methods: Adult patients with recurrent HCV infection post-OLT with null response to peginterferon/ribavirin for 12 wk (<2 log reduction) received four-wk lead-in PEG-IFN alfa-2b (1.0 μg/kg/wk) plus RBV (600-1000 mg/d) followed by addition of telaprevir 750 q8. All patients were converted to cyclosporine from tacrolimus (TAC). Results: Seven patients (3 M, 4 F), mean age 56 yr, were treated. Three were <1 yr post-OLT, six had cirrhosis and one bridging fibrosis. Three of seven achieved sustained virologic response. All patients required RBV dose reduction, 6/7 required erythropoietin, 5/7 required filgrastim, and 2/7 required eltrombopag for platelets <20 000 μL. There were no supratherapeutic/subtherapeutic CYA levels encountered, no episodes of renal insufficiency. Conclusions: Conversion to CYA followed by four-wk peginterferon/ribavirin lead-in with addition of telaprevir can lead to significant clearance rates at week 24 in null responders with advanced fibrosis although high rates of anemia/RBV dose reduction, growth factor, and transfusion requirements were noted.

Original languageEnglish (US)
Pages (from-to)722-727
Number of pages6
JournalClinical Transplantation
Issue number6
StatePublished - Jun 2014
Externally publishedYes


  • Cirrhosis
  • Direct-acting antiviral agents
  • Drug-drug interactions
  • Hepatitis C
  • Orthotopic liver transplant

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant'. Together they form a unique fingerprint.

Cite this